Niraparib-A new anticancer drug
Niraparib,(Zejula)
formerly known as MK-4827, is an orally active and potent poly (ADP-ribose)
polymerase, or PARP, inhibitor. A Phase 1/2 monotherapy study has been
completed in more than 100 patients with advanced solid tumors. Based upon the
results of the Phase 1/2 study and published data from other trials of PARP
inhibitors, TESARO is evaluating niraparib at a dose of 300 milligrams once
daily in two Phase 3 studies.
Niraparib is a
prescription medicine used for the maintenance treatment of adults with ovarian
cancer, fallopian tube cancer, or primary peritoneal cancer, when the cancer
comes back. Niraparib is used after the cancer has responded (complete or
partial response) to treatment with platinum-based chemotherapy. It is not
known if Niraparib is safe and effective in children.
No comments:
Post a Comment